¼±ÅÃÀû Cyclooxygenase-2 ¾ïÁ¦Á¦ÀÎ Celecoxib°¡ »óÀÌÇÑ Cyclooxygenase-2 ¹ßÇö·®À» °¡Áø Àΰ£ ¾Ï¼¼Æ÷Áֵ鿡 ´ëÇÏ¿© À¯µµÇÏ´Â ¹æ»ç¼± °¨¼ö¼º ÁõÁø ÀÛ¿ë
The Enhancement of Radiosensitivity by Celecoxib, Selective Cyclooxygenase-2 Inhibitor, on Human Cancer Cells Expressing Differential Levels of Cyclooxygenase-2.
¼Ò¼Ó »ó¼¼Á¤º¸
ǥȫ·Ä/Pyo HR
½ÅÀ¯±Ù/±èÇö¼®/¼ºÁø½Ç/¼Ã¢¿Á/±è±Í¾ð/Shin YK/Kim HS/Seong JS/Suh CO/Kim GE
KMID : 0859320030210030216
Abstract
¸ñÀû: Cyclooxygenase-2(COX-2)¸¦ °ú¹ßÇöÇÏ´Â A549 Àΰ£Æó¾Ï¼¼Æ÷ÁÖ¿Í ¹ßÇöÇÏÁö ¾Ê´Â MCF-7 Àΰ£À¯¹æ¾Ï¼¼Æ÷ÁÖ¿¡¼ ¼±ÅÃÀû COX-2 ¾ïÁ¦Á¦ÀÎ celecoxibÀÇ ¹æ»ç¼± °¨¼ö¼º ÁõÁø ÀÛ¿ëÀ» °üÂûÇÏ°íÀÚ ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý: A549 ¼¼Æ÷¿Í MCF-7 ¼¼Æ÷¿¡ ´ëÇؼ ¹æ»ç¼± ȤÀº ¹æ»ç¼±°ú celecoxib¸¦ º´¿ë Åõ¿©ÇÑ ÈÄ¿¡ clonogenic radiation survival ½ÇÇèÀ» ½ÃÇàÇÏ¿´´Ù. °°Àº ½ÇÇèÀ» °¢°¢ 10%¿Í 1%ÀÇ FBS¸¦ Æ÷ÇÔÇÑ ¹èÁö¿¡¼ ¹Ýº¹ÇÏ¿´´Ù. °¢ ¼¼Æ÷¿¡ ¹æ»ç¼±°ú celecoxib¸¦ µ¿½Ã ȤÀº ´Üµ¶ Åõ¿©ÇÑ ÈÄ¿¡ °¢ ½ÇÇè ±×·ìÀÇ ¼¼Æ÷»ç¸êÀ» ÃøÁ¤ÇÏ¿´´Ù.
°á°ú: ¾à¹° Åõ¿© ±â°£ µ¿¾È 10%ÀÇ Ç÷ûÀ» Æ÷ÇÔÇÑ ¹èÁö Á¶°Ç¿¡¼ ¹è¾çµÈ A549 ¼¼Æ÷¿¡¼´Â, 30¥ìM °ú 50¥ìM ³óµµÀÇ celecoxib°¡ Åõ¿©µÈ »óÅ¿¡¼ surviving fraction=0.1¿¡¼ÀÇ Radiation enhancement ratio (RER)°¡ °¢°¢ 1.58°ú 1.81·Î celecoxib°¡ A459 ¼¼Æ÷ÀÇ ¹æ»ç¼± °¨¼ö¼ºÀ» Áõ°¡½ÃÄ×´Ù. ÀÌ·¯ÇÑ ¹æ»ç¼± °¨¼ö¼ºÀÇ Áõ°¡´Â ¼¼Æ÷¸¦ 1%ÀÇ Ç÷ûÀ» Æ÷ÇÔÇÑ ¹èÁö¿¡¼ ¹è¾çÇÏ¿´À»¶§´Â ¼Ò½ÇµÇ¾ú´Ù. MCF-7 ¼¼Æ÷¿¡¼´Â 10%¿Í 1% Ç÷ûÀ» Æ÷ÇÔÇÑ °¢°¢ÀÇ ¹èÁöÁ¶°Ç ÇÏ¿¡¼ celecoxib¿¡ ÀÇÇÑ ¹æ»ç¼± °¨¼ö¼ºÀÇ º¯È°¡ °üÂûµÇÁö ¾Ê¾Ò´Ù. A549¿Í MCF-7 ¼¼Æ÷ÀÇ °¢ ±×·ì¿¡¼ ¼¼Æ÷»ç¸êÀ» ÃøÁ¤ÇÑ °á°ú celecoxib¿Í ¹æ»ç¼±ÀÌ º´¿ë Åõ¿©µÇ¾úÀ» ¶§ À¯µµµÇ´Â ¼¼Æ÷»ç¸êÀº »óÈ£ »ó½ÂÀûÀÌÁö ¾ÊÀº °ÍÀ¸·Î ³ªÅ¸³µ´Ù.
°á·Ð: COX-2 ¼±ÅÃÀû ¾ïÁ¦Á¦ÀÎ celecoxib´Â COX-2¸¦ °ú¹ßÇöÇÏ´Â A549 ¼¼Æ÷¿¡¼ ¼±ÅÃÀûÀ¸·Î ¹æ»ç¼± °¨¼ö¼ºÀ» ÁõÁø½ÃÄ×À¸¸ç, Àú³óµµÀÇ Ç÷ûÀ» Æ÷ÇÔÇÑ ¹èÁö Á¶°Ç¿¡¼´Â ÀÌ·¯ÇÑ È¿°ú°¡ ¼Ò½ÇµÇ¾ú´Ù. COX-2¸¦ ¹ßÇöÇÏÁö ¾Ê´Â MCF-7 ¼¼Æ÷ÁÖ¿¡¼´Â celecoxib¿¡ ÀÇÇؼ ¹æ»ç¼± °¨¼ö¼ºÀÌ º¯ÈµÇÁö ¾Ê¾ÒÀ¸¸ç, ÀÌ·¯ÇÑ celecoxibÀÇ ¹æ»ç¼± °¨¼ö¼º ÁõÁø ÀÛ¿ë ±âÀü¿¡ ¼¼Æ÷ »ç¸êÀº °ü¿©ÇÏÁö ¾Ê´Â °ÍÀ¸·Î º¸ÀδÙ.
Purpose: To investigate the modulation of radiosensitivity by celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, on cancer cells over- and under-expressing COX-2.
Materials and Methods: A clonogenic radiation survival analysis was performed on A549 human lung and MCF-7 human breast cancer cell lines was measured after treatment with radiation and/or celecoxib.
Results: Celecoxib enhanced the radiation sensitivity of the A549 cells in the medium containing the 10% FBS, with radiation enhancement ratios of 1.58 and 1.81 respectively, at surviving fractions of 0.1, with 30¥ìM and 50¥ìM celecoxib. This enhanced radiosensitivity disappeared in the medium containing the 1% FBS. Celecoxib did not change the radiation sensivitity of the MCF-7 cells in either media. The induction of apoptosis by celecoxib and radiation was not synergistic in either cell line.
Conclusion: Celecoxib, a selective COX-2 inhibitor, preferentially enhanced the effect of radiation on COX-2 over-expressing cancer cells compared to the cells with a low expression, and this effect disappeared on incubation of the cells during drug treatment in the medium with suboptimal serum concentration. Apoptosis did not appear to be the underlying mechanism of this radiation enhancement effect due to celecoxib on the A549 cells. These findings suggest radiosensitization by a selective COX-2 inhibitor is COX-2 dependent.
Å°¿öµå
Cyclooxygenase-2; COX-2; ¹æ»ç¼±; A549; MCF-7;Radiation
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸